Holen Sie sich die Stockscreener-App
2.52
4.91%
-0.13
Handel nachbörslich:
2.62
0.10
+3.97%
Schlusskurs vom Vortag:
$2.65
Offen:
$2.63
24-Stunden-Volumen:
54,577
Relative Volume:
0.01
Marktkapitalisierung:
$9.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.61M
KGV:
-2.80
EPS:
-0.9
Netto-Cashflow:
$-22.91M
1W Leistung:
-14.86%
1M Leistung:
-20.75%
6M Leistung:
+426.65%
1J Leistung:
+210.80%
1-Tages-Spanne:
$2.44
$2.665
1-Wochen-Bereich:
$2.44
$3.1295
52-Wochen-Spanne:
$0.0815
$4.44
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Firmenname
Bioline Rx Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
2.52 | 9.86M | 0 | -60.61M | -22.91M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-05-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-02-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-08-17 | Bestätigt | Maxim Group | Buy |
| 2015-07-27 | Bestätigt | ROTH Capital | Buy |
| 2015-06-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Bioline Rx Ltd Adr Aktie (BLRX) Neueste Nachrichten
BioLineRx stock rating cut to Hold at Jones Trading - Investing.com
BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com
H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India
BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks
BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks
BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks
BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks
Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
BLRX: Aphexda Transition Progressing - Research Tree
BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India
BioLineRx announces strategic shift with licensing deals - Investing.com
BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks
BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks
BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India
BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com
BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks
BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com
BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India
BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com
BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks
BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
BioLineRx earnings beat by $0.04, revenue topped estimates - Investing.com India
Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com
Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa
BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
Options Volatility and Implied Earnings Moves Today, November 25, 2024 - TipRanks
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance
BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com
BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks
SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga
BioLineRx to Report Q3 2024 Financial Results on November 25 - StockTitan
BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks
BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India
BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks
BioLineRx secures US patent for cancer drug motixafortide - Investing.com
BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK
BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com
Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle
BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com
BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle
Finanzdaten der Bioline Rx Ltd Adr-Aktie (BLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):